title: [Pharmacological treatment of the premature ejaculation].
abstract: Biomedical approach to premature ejaculation (PE) has permited a better phisiopatologycal knowledge and so the use of pharmacological agents for the treatment of this sexual dysfuncion. Most of the studies to evaluate the eficacy of these drugs were not carried at all the parameters which actually define PE: intravaginal ejaculatory latencie time (IELT) tested with watch, ejaculation control self perception cuantification (questionaries) and cuantification of generated consequences in patient and partner, if it existes. For this reason, it is difficult to analyse the scientific evidence and we use medicines with no approved indication for PE ("off label"). This text is a review of pharmacologycal agents with no approved indication (PDE type 5 inhibitors, α-blockers, tramadol, SSRI, clomipramine), and pharmacologycal agents developed to be used in the treatment of PE and having got indication in this sexual dysfunction or "on label" drugs (topic anesthesics, dapoxetine).
authors.affiliation: Instituto Europeo de Sexología, Elviria Medical Centre, Marbella, Málaga, España. Electronic address: anarosajurado@yahoo.es.
authors.forename: A R
authors.initials: AR
authors.lastname: Jurado López
mesh_terms: D004542:Ejaculation / Q000187:drug effects* / Q000502:physiology; D005260:Female; D006801:Humans; D008297:Male; D056687:Off-Label Use; D061686:Premature Ejaculation / Q000188:drug therapy* / Q000503:physiopathology; D012747:Sexual Partners / Q000523:psychology*; D011795:Surveys and Questionnaires
keywords: Dapoxetina; Dapoxetine; Eyaculación prematura; Farmacological treatment; Premature ejaculation; Tratamiento farmacológico